Lixte Biotechnology (NASDAQ:LIXT) Trading 20.5% Higher – What’s Next?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares traded up 20.5% during mid-day trading on Monday . The company traded as high as $1.48 and last traded at $1.41. 55,085 shares were traded during mid-day trading, a decline of 70% from the average session volume of 186,707 shares. The stock had previously closed at $1.17.

Lixte Biotechnology Stock Performance

The firm has a market capitalization of $3.78 million, a price-to-earnings ratio of -0.82 and a beta of 0.40. The business has a 50 day simple moving average of $1.26 and a 200-day simple moving average of $1.67.

Lixte Biotechnology (NASDAQ:LIXT) last issued its earnings results on Monday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter.

Institutional Trading of Lixte Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of LIXT. Atlas Legacy Advisors LLC acquired a new stake in shares of Lixte Biotechnology during the 4th quarter worth about $26,000. TIAA Trust National Association acquired a new stake in shares of Lixte Biotechnology during the 4th quarter worth about $207,000. Finally, FNY Investment Advisers LLC boosted its holdings in Lixte Biotechnology by 172.8% during the 1st quarter. FNY Investment Advisers LLC now owns 107,000 shares of the company’s stock valued at $129,000 after acquiring an additional 67,781 shares during the period. 5.10% of the stock is owned by institutional investors and hedge funds.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.